BIO-RAD LAB-A
BIO-RAD LAB-A operates in Diversified Metals & Mining.
BIO-RAD LAB-A (BUWA) - Total Liabilities
Latest total liabilities as of September 2024: €3.12 Billion EUR
Based on the latest financial reports, BIO-RAD LAB-A (BUWA) has total liabilities worth €3.12 Billion EUR as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BIO-RAD LAB-A - Total Liabilities Trend (2016–2023)
This chart illustrates how BIO-RAD LAB-A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
BIO-RAD LAB-A Competitors by Total Liabilities
The table below lists competitors of BIO-RAD LAB-A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Public Company Management Corp
PINK:PCMC
|
USA | $480.93K |
|
AppSpotr AB
ST:APTR
|
Sweden | Skr5.53 Million |
|
Art Nirman Limited
NSE:ARTNIRMAN
|
India | ₹504.69 Million |
|
Mercator Limited
NSE:MERCATOR
|
India | ₹24.65 Billion |
|
Bait Bakfar Ltd
TA:BKFR
|
Israel | ILA990.05 Million |
|
ALNYLAM PHARMA
MU:DUL
|
Germany | €4.17 Billion |
|
PT Sari Kreasi Boga Tbk
JK:RAFI
|
Indonesia | Rp185.32 Billion |
Liability Composition Analysis (2016–2023)
This chart breaks down BIO-RAD LAB-A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BIO-RAD LAB-A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BIO-RAD LAB-A (2016–2023)
The table below shows the annual total liabilities of BIO-RAD LAB-A from 2016 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | €3.56 Billion | -8.45% |
| 2022-12-31 | €3.89 Billion | -5.54% |
| 2021-12-31 | €4.11 Billion | +33.03% |
| 2020-12-31 | €3.09 Billion | +37.22% |
| 2019-12-31 | €2.25 Billion | +41.68% |
| 2018-12-31 | €1.59 Billion | +18.47% |
| 2017-12-31 | €1.34 Billion | +6.25% |
| 2016-12-31 | €1.26 Billion | -- |